News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Connetics Corporation (CNCT) Launches Verdeso Foam For The Treatment Of Mild-to-Moderate Atopic Dermatitis In Children And Adults


11/9/2006 11:51:11 AM

PALO ALTO, Calif.--(BUSINESS WIRE)--Connetics Corporation (NASDAQ: CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, today announced the nationwide U.S. commercial launch of Verdeso™ (desonide) Foam, 0.05%, for the treatment of mild-to-moderate atopic dermatitis in adults and children as young as three months of age. Verdeso, a low-potency topical steroid, is the first commercial product formulated in Connetics’ proprietary VersaFoam-EF™ emulsion formulation foam vehicle, and is the first Connetics product to include a pediatric indication. Verdeso is available in 50g and 100g trade unit sizes.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES